These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 33484966)

  • 1. METTL3 restrains papillary thyroid cancer progression via m
    He J; Zhou M; Yin J; Wan J; Chu J; Jia J; Sheng J; Wang C; Yin H; He F
    Mol Ther; 2021 May; 29(5):1821-1837. PubMed ID: 33484966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3 regulates thyroid cancer differentiation and chemosensitivity by modulating PAX8.
    Kang N; Zhao Z; Wang Z; Ning J; Wang H; Zhang W; Ruan X; Gao M; Zheng X
    Int J Biol Sci; 2024; 20(9):3426-3441. PubMed ID: 38993572
    [No Abstract]   [Full Text] [Related]  

  • 3. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer.
    Ning J; Hou X; Hao J; Zhang W; Shi Y; Huang Y; Ruan X; Zheng X; Gao M
    Cell Death Differ; 2023 Oct; 30(10):2265-2279. PubMed ID: 37648786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.
    Huang J; Sun W; Wang Z; Lv C; Zhang T; Zhang D; Dong W; Shao L; He L; Ji X; Zhang P; Zhang H
    J Exp Clin Cancer Res; 2022 Jan; 41(1):42. PubMed ID: 35090515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m
    Chai RC; Chang YZ; Chang X; Pang B; An SY; Zhang KN; Chang YH; Jiang T; Wang YZ
    J Hematol Oncol; 2021 Jul; 14(1):109. PubMed ID: 34246306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition.
    Zhu Y; Peng X; Zhou Q; Tan L; Zhang C; Lin S; Long M
    Cell Death Dis; 2022 Apr; 13(4):358. PubMed ID: 35436987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. m6A Writer METTL3-Mediated lncRNA LINC01125 Prevents the Malignancy of Papillary Thyroid Cancer.
    He T; Xia H; Chen B; Duan Z; Huang C
    Crit Rev Immunol; 2023; 43(3):43-53. PubMed ID: 37824376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The m
    Cheng M; Sheng L; Gao Q; Xiong Q; Zhang H; Wu M; Liang Y; Zhu F; Zhang Y; Zhang X; Yuan Q; Li Y
    Oncogene; 2019 May; 38(19):3667-3680. PubMed ID: 30659266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTO/IGF2BP2-mediated N6 methyladenosine modification in invasion and metastasis of thyroid carcinoma via CDH12.
    Chen Z; Zhong X; Xia M; Liu C; Tang W; Liu G; Yi Y; Guo Y; Jiang Q; Zu X; Zhong J
    Cell Death Dis; 2024 Oct; 15(10):733. PubMed ID: 39379360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m
    Liu L; Wu Y; Li Q; Liang J; He Q; Zhao L; Chen J; Cheng M; Huang Z; Ren H; Chen J; Peng L; Gao F; Chen D; Wang A
    Mol Ther; 2020 Oct; 28(10):2177-2190. PubMed ID: 32621798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METTL3-Induced miR-222-3p Upregulation Inhibits STK4 and Promotes the Malignant Behaviors of Thyroid Carcinoma Cells.
    Lin S; Zhu Y; Ji C; Yu W; Zhang C; Tan L; Long M; Luo D; Peng X
    J Clin Endocrinol Metab; 2022 Jan; 107(2):474-490. PubMed ID: 34562008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METTL3/YTHDF2 m
    Xie H; Li J; Ying Y; Yan H; Jin K; Ma X; He L; Xu X; Liu B; Wang X; Zheng X; Xie L
    J Cell Mol Med; 2020 Apr; 24(7):4092-4104. PubMed ID: 32126149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HNRNPC modulates PKM alternative splicing via m6A methylation, upregulating PKM2 expression to promote aerobic glycolysis in papillary thyroid carcinoma and drive malignant progression.
    Rong S; Dai B; Yang C; Lan Z; Wang L; Xu L; Chen W; Chen J; Wu Z
    J Transl Med; 2024 Oct; 22(1):914. PubMed ID: 39380010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.
    He J; Zhou M; Li X; Gu S; Cao Y; Xing T; Chen W; Chu C; Gu F; Zhou J; Jin Y; Ma J; Ma D; Zou Q
    Oncogene; 2020 Mar; 39(13):2658-2675. PubMed ID: 32005974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. m
    Hou J; Shan H; Zhang Y; Fan Y; Wu B
    Am J Otolaryngol; 2020; 41(4):102547. PubMed ID: 32474328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m
    Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
    Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. METTL3-dependent N
    Chien CS; Li JY; Chien Y; Wang ML; Yarmishyn AA; Tsai PH; Juan CC; Nguyen P; Cheng HM; Huo TI; Chiou SH; Chien S
    Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33579825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
    Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
    J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.